PainReform to Present at Noble Capital Markets Eighteenth Annual Investor Conference on April 20

PainReform Ltd

TEL AVIV, Israel, April 12, 2022 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX)a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapies, today announced that Ilan Hadar, Managing Director of PainReform, will be presenting at Noble Capital Markets’ eighteenth annual investor conference to be held on June 20 and April 21, 2022 at the Hard Rock Hotel & Casino in Hollywood, Florida.

Mr. Hadar will present on Wednesday, April 20and at 12:00 p.m. EST in the Seminole C Ballroom. Investors interested in meeting with management can meet at the breakout session on Wednesday, April 20and at 4:00 p.m. Eastern Time at Table 9.

A high-definition video webcast of the presentation will be available the following day on the Company’s website. https://painreform.com/and as part of a comprehensive catalog of presentations available on the Noble Capital Markets conference website www.nobleconference.com and on Channelcheck www.channelchek.com, the investor portal created by Noble. The webcast will be archived on the company’s website, the NobleCon website and on Channelchek.com for 90 days after the event.

About Noble Capital Markets, Inc.

Noble Capital Markets (“Noble”) is a research-driven investment bank that has been supporting small and micro cap stocks since 1984. As a FINRA and SEC approved broker-dealer, Noble provides quality equity research services institutional, corporate and investment banking and order execution. services. In 2005, Noble established NobleCon, an investor conference that has grown significantly over the past decade. Noble launched www.channelchek.com in 2018 – an investor community dedicated exclusively to public small and micro cap stocks and their industries. Channelchek is the first service to bring institutional quality research to the public, FREE at all levels without a subscription. More than 6,000 public emerging growth companies are listed on the site, with growing content including research, webcasts, podcasts and balanced news.

About pain reform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s flagship product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is a clear viscous oil-based solution that is deposited directly into the surgical wound bed prior to closure to provide localized and prolonged postoperative analgesia. The company’s proprietary extended-release drug delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeat doses while reducing the potential need to use opiates. For more information, visit www.painreform.com.

Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “could”, “seek”, “target”, “will”, “project”, “anticipate”, “continue” or “anticipate” or their negative forms or variations of these words or other comparable words or by the fact that such statements do not relate strictly to historical matters.These forward-looking statements are based on assumptions and assessments made in light of experience and management’s perception of historical trends, current conditions, expected future developments and other factors deemed appropriate.The forward-looking statements contained in this press release are made as of the date of this press release, and we undertake no obligation to update or revise such statements, whether as of further news rations, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are beyond our control. Many factors could cause our actual operations or results to differ materially from the operations and results anticipated in the forward-looking statements, including, but not limited to, the following: our history of significant losses, our need to mobilize additional capital and our ability to obtain additional capital on acceptable terms, if at all; our dependence on the success of our initial product candidate, PRF-110; results of preclinical studies, clinical trials and other research regarding PRF-110 and future product candidates; the impact of the COVID-19 pandemic on our operations; our limited experience in managing clinical trials; our ability to retain key personnel and recruit additional employees; our reliance on third parties for the conduct of clinical trials, manufacturing and product development; the impact of competition and new technologies; our ability to comply with regulatory requirements relating to the development and commercialization of our product candidates; the commercial success and market acceptance of our product candidates; our ability to establish sales and marketing capabilities or enter into agreements with third parties and our reliance on third-party distributors and resellers; our ability to establish and maintain strategic partnerships and other business collaborations; the implementation of our business model and strategic plans for our businesses and product candidates; the extent of protection we are able to establish and maintain for intellectual property rights and our ability to operate our business without infringing the intellectual property rights of others; the overall global economic environment; our ability to develop an active trading market for our common stock and whether the market price of our common stock is volatile; and statements regarding the impact of the political and security situation in Israel on our business. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F and in other documents we have filed and may file. with the Securities and Exchange Commission in the future.

Contact:

Crescendo Communications, LLC
Tel: 212-671-1021
E-mail: [email protected]

Ilan Hadar
Chief executive officer
PainReform Ltd.
Tel: +972-54-5331725
E-mail: [email protected]